There can be no innovative therapeutic products without an innovative technological platform
Oncodesign Precision Medicine (OPM) is the essence of the dream that led to the creation of Oncodesign SA in 1995. OPM is a biotechnology company specialising in precision medicine applied to the discovery of treatments for metastatic and resistant cancers. Thanks to the technologies available through Oncodesign Services (ODS) and OPM, we have access to technologies that allow us to select the best drug candidates, discover the most effective kinase inhibitors and theranostic tools, and select the most relevant therapeutic targets in oncology. OPM currently has two kinase inhibitors in the clinical phase:
- OPM-101, intended for the treatment of chronic digestive immune-inflammatory diseases and in immuno-oncology, has shown a substantial therapeutic margin and no toxicity during its Phase I in healthy volunteers. The Phase 1b/2a protocol in Oncology was submitted at the end of March 2025.
- OPM-201, initially licensed to Servier and intended for the treatment of Parkinson's disease, completed its Phase I in healthy volunteers at the end of 2024 and has rejoined OPM's portfolio.
- OncoSNIPER, for the selection of therapeutic targets using artificial intelligence, with which we have a partnership with Servier for target research in pancreatic cancer,
- PROMETHE® for the design and selection of radiolabeled biological molecules for systemic radiotherapy, with which we are in partnership discussions with vectorization industry players.
